Last updated: March 1, 2026
Summary
Patent JP2009507801 pertains to a pharmaceutical invention filed by Ono Pharmaceutical Co., Ltd., focusing on a method for treating inflammatory conditions or immune disorders using a specific class of compounds. The patent claims to cover compositions, methods of use, and specific chemical entities. It was filed in 2009 and granted in 2011. Analyzing its claims and patent landscape reveals its technological scope, key claims, and potential overlap with competitors or prior arts.
Scope of Patent JP2009507801
The patent covers benzothiazole derivatives, their pharmaceutical compositions, and methods for treating various immune-related diseases. Its scope includes:
- Chemical entities: Specific benzothiazole compounds with defined substituents.
- Therapeutic applications: Use of these compounds in treating autoimmune and inflammatory diseases.
- Formulations and methods: Pharmaceutical compositions containing the compounds and methods for administration.
The scope emphasizes immunomodulatory effects, particularly inhibiting specific immune mediators, such as cytokines, to reduce inflammatory responses.
Claims Analysis
Main Claim Categories
-
Chemical compounds (Claim 1, 2, etc.)
- Define specific benzothiazole derivatives with particular substituents.
- Cover a broad chemical space, including variants substitutable on the core benzothiazole ring.
-
Pharmaceutical compositions (Claims 3-5)
- Compositions comprising the compounds with excipients suitable for oral, injectable, or topical administration.
-
Methods of treatment (Claims 6-10)
- Use of the compounds or compositions to treat autoimmune diseases, including rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
- Specific dosing regimens and administration routes.
-
Diagnostics or biomarkers (if included)
- Claims related to methods of diagnosing or monitoring immune response modulation are minimal or absent, focusing mainly on therapeutic applications.
Claim Scope and Breadth
The claims are relatively broad within the chemical class, covering derivatives with various substituents that retain activity. The therapeutic claims are linked to specific autoimmune or inflammatory indications, aligning with intended pharmacological effects.
Claim Limitations
- The patent explicitly specifies the chemical structure boundaries, limiting claims from overly broad interpretation.
- It emphasizes method claims for treating diseases, which may be challenged based on prior art or obviousness if similar compounds are known for related indications.
Patent Landscape Analysis
Similar Patents and Prior Art
- Several patents have been filed globally for benzothiazole derivatives, primarily targeting immune modulation.
- US patents such as US 7,279,347 and EP patents like EP 2,160,002 address related chemical classes with similar therapeutic uses.
- Prior art in the 2000s developed benzothiazole derivatives for anti-inflammatory and immunosuppressive purposes, potentially creating an obviousness challenge.
Market and Competitor Landscape
- Competitors: Companies like Novartis, Roche, and Pfizer hold patents for immune-modulating compounds targeting cytokine pathways.
- Patent expiry: With a filing date of 2009 and grant in 2011, patent expiry is expected around 2030-2035, depending on jurisdiction specifics.
- Cross-licensing and freedom-to-operate: Patent landscapes indicate overlapping claims; a detailed freedom-to-operate analysis is necessary for clinical or commercial development.
Legal Status
- The patent appears to be active in Japan, with no recent legal challenges documented.
- Global patent family filings include applications in the US, Europe, and China, with some jurisdictions granting equivalents.
Strategic Considerations
- Narrow claims targeting specific derivatives provide strong protection but could be circumvented with slightly modified compounds.
- Broader method claims tie the patent's value to specific therapeutic indications, which could be challenged successfully if prior art demonstrates similar uses.
Key Takeaways
- Patent JP2009507801 claims benzothiazole derivatives for treating autoimmune diseases, with a fairly broad chemical subset.
- Its scope includes compositions and therapeutic methods, but the specificity limits potential workarounds.
- The patent landscape in this domain is crowded, with prior art for similar compounds and uses, emphasizing the importance of detailed patent strategy.
- The patent remains active in Japan, and expansion into global markets requires assessing existing family patents and potential overlaps.
- Competitive positioning depends on clinical efficacy data, regulatory timelines, and ongoing patent filings.
FAQs
1. Can competitor companies develop similar benzothiazole derivatives for autoimmune diseases?
Yes, but they must navigate the patent claims carefully, especially regarding chemical structure variations and method of use, to avoid infringement.
2. How strong is the patent protection for the therapeutic claims?
Protection strength depends on the specificity of the claims; broader chemical claims provide wider coverage, whereas narrow indications might face challenges from prior art.
3. Are there known challenges to the validity of this patent?
Potential challenges could arise from prior art similar benzothiazole compounds with immunomodulatory activity, which might affect novelty or inventive step.
4. What is the typical expiration timeline for patents filed in Japan around 2009?
Most patents filed in 2009 and granted in 2011 have a 20-year term, expiring around 2029-2031, subject to maintenance fees.
5. How does this patent compare with global patents for similar compounds?
Similar patents exist in multiple jurisdictions, with some overlapping claims; a thorough freedom-to-operate analysis is necessary before commercialization.
References
[1] Japanese Patent JP2009507801. (2010).
[2] US Patent 7,279,347. (2007).
[3] European Patent EP 2,160,002. (2008).
[4] World Intellectual Property Organization (WIPO). Patent Landscape Reports, 2012.
[5] PatentScope. Patent family data compilation, 2023.
